<DOC>
	<DOCNO>NCT02389452</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety efficacy single 6 mL intraarticular ( IA ) injection Synvisc-One participant India symptomatic osteoarthritis ( OA ) knee ( ) . Secondary Objective : To evaluate safety short-term efficacy repeat treatment Synvisc-One .</brief_summary>
	<brief_title>Study Safety Efficacy 6 mL Synvisc-One ( Hylan G-F 20 ) Indian Patients With Symptomatic Osteoarthritis Knee ( ) After Initial Repeat Treatment</brief_title>
	<detailed_description>A period approximately 19 month anticipate time first participant enrol study completion study ( last participant ) . Individual participant participation last 7 13 month depend time repeat treatment .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Male female participant age 30 year old , active lifestyle . The participant must able read , understand , sign inform consent form , understand requirement followup visit , must willing provide information schedule evaluation . The participant diagnosis OA target knee confirm recent Xray ( mild moderate joint space narrow and/or osteophyte ( ie , Kellgren Lawrence [ KL ] Grade IIII ) , predominant tibiofemoral compartment . WOMAC A1 baseline 100 mm visual analog scale ( VAS ) score 4080 mm ( moderate severe walk pain ) target knee . Participants bilateral disease may include study strict condition : Only one knee include efficacy assessment consider target knee ( bad knee WOMAC A1 pain scale select ) . The selected knee must meet inclusion exclusion criterion . The nontarget knee may also treat SynviscOne need meet KL grade knee specific inclusion criterion describe . The criterion apply . If female , must negative urine pregnancy test continue use medically acceptable form contraception duration study . Otherwise , females must surgically sterile postmenopausal ( documented medical history ) least 1 year . Significant ( require surgical correction ) valgus varus deformity knee , ligamentous laxity , meniscal instability . Concomitant inflammatory disease/condition may affect joint ( eg , rheumatoid arthritis , metabolic bone disease , psoriasis , gout , pseudogout , chondrocalcinosis ) . History sepsis joint clinical concern subacute infectious process target joint . History surgery target knee . Planned surgery lower extremity joint . Clinically significant venous lymphatic stasis present leg ( ) . Clinically apparent tense effusion inflammation target knee . Skin disease infection area injection site . Any musculoskeletal condition would impede measurement efficacy target knee . Pregnant lactating woman . Hypersensitivities avian protein and/or component hyaluronanbased injection . Treatment hyaluronic acid ( HA ) derivatives previous 6 month . Treatment IA steroids previous 3 month . Any contraindication IA injection , eg , anticoagulant therapy clinical concern potential coagulopathy ( eg , liver disease ) . Any significant medical condition ( eg , significant psychiatric neurological disorder active alcohol/drug abuse ) , medical condition unstable/poorly control factor ( eg , plan relocation ) Investigator felt would interfere study evaluation study participation . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>